CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...